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Abstract 
Cancer is a hyperplastic cellular malignancy that affected 1,436,000 people 
(newly diagnosed cases) in the United States last year. The top three most frequent forms 
of cancer were lung, prostate, and breast. Oncogenesis is associated with both genetic 
predisposition and environmental onslaught, with a mixture of the two being required for 
the malignancy to progress. Tumor markers, circulating serum factors, are used in the 
diagnosis of cancer. Prostate cancer is one of the most prevalent forms of this 
malignancy, affecting 230,110 men in 2004 alone. Diagnosis of prostate cancer is 
currently performed using results of an assay for prostate specific antigen (PSA). 
However, the theory has been advanced that either prostatic acid phosphatase (PAP) or 
testosterone may be a more accurate tumor marker than PSA. This study examines the 
efficacy of all three of these tests and specifically compares a PAP assay to the current 
standard test for PSA. A Diagnostics Automation, Inc. enzyme immunosorbent assay was 
used to measure prostatic acid phosphatase in 102 healthy adult males and 449 adult male 
patients. Predictive values were determined for PAP and compared with those of the PSA 
assay performed on the same samples. The results were as follows: diagnostic percent 
sensitivity was (20.73, PAP); (0.00, Testosterone); (30.12, PSA), the diagnostic percent 
specificity was: (80.38, PAP); (98.80, Testosterone); (91.29, PSA), and the diagnostic 
percent efficiency was: (71.51, PAP); (82.40, Testosterone); (81.73, PSA). From these 
data, it was concluded that the test for prostate specific antigen is the most accurate and 
efficient screen for prostate cancer. Finally, predictive values were determined for all 
three markers evaluated together.  
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Introduction 
Birindelli, et. al (2000) described cancer as “the result of circumvention of the 
apoptotic machinery, promotion of cell division and cell proliferation, loss of cell 
differentiation pathways, and disruption of cell-cell communication and interaction.” 
(p.45) The process of carcinogenesis is composed of many steps involving specific genes 
prone to producing such a state and signals provided and controlled by the products 
thereof (Birindelli, Aiello, Lavarino, et. al, 2000). The resulting disease state produces 
malignant tissue that invades and destroys nearby tissue and can metastasize to other 
areas of the body (Cook, 1996). There is a large genetic component to cancer since it 
arises from alterations in cellular DNA or in the transcriptional or translational processes 
that produce abnormalities in gene expression (Loescher, Whitesell, 2003). Although all 
cancer is not hereditary, over 200 hereditary cancer syndromes have been described, and 
an individual’s risk for cancer has been seen to be increased if multiple family members 
are afflicted (Hunt, 2005).  
Cancer is aggressive, degenerative and affects many people worldwide. There 
were 565,600 cancer deaths in 2008 in the United States alone, and 1,437,200 new 
diagnoses (IARC, 2010). In 1999, there were an estimated 8,100,000 cases diagnosed 
worldwide in that single year (Alberts, Hess, 2005). Cancer is classified into three 
categories: sarcomas, affecting bone and fibrous tissue (muscle, blood vessels); 
carcinomas, affecting tissues such as the epithelium, lungs, breast, and colon; and 
leukemias and lymphomas, affecting the cells of the bone marrow and lymph nodes 
(Rosenbaum, 1983).  
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 Prostate cancer is a carcinoma involving the epithelial cells of the prostate, a 
gland in the lower abdomen of males, just below the bladder and in front of the rectum, 
wrapping around the urethra. It is normally about 1.5” in diameter and produces prostatic 
fluid (a thick fluid that is part of semen) while simultaneously acting as a valve to allow 
sperm and urine to flow in the correct direction. Masses of abnormally proliferating cells 
swell the size of the prostate in malignant conditions and if they breach the fibrous 
membrane surrounding this organ, they can quickly circulate to other tissues to produce 
aggressive metastasis (Bostwick, MacLennan, Larson, 1996). Prostate cancer most often 
metastasizes to the lymph nodes, pelvic bones and spine or vertebrae, axial skeleton and 
proximal long bones, lungs, liver, bladder, and rectum (Cook, 1996).  
The incidence of prostate cancer in 2008 was 186,320 in the United States (IARC, 
2010). Prostate cancer is the most common cancer diagnosed in North American men 
(Alberts, Hess, 2005). It also affects many thousands more in other countries worldwide. 
Thus, the problem of prostate cancer is both widespread and significant.  
Of primary importance in the study of prostate cancer is the method of diagnosis. 
In addition to medical history, physical examination, and visual and tactile (such as a 
rectal examination) methods of tumor determination, an accurate screening test must be 
developed to increase early detection, efficacy of treatment, and survival rates. 
Alterations of genes associated with cancer provide products that can be used as 
molecular markers to indicate a cancer disease state (Birindelli, Aiello, Lavarino, et. al, 
2000). Prostate specific antigen (PSA) is currently accepted as the most accurate 
screening test for the detection of prostate cancer (Haese, Becker, Diamandis, et. al, 
2002). However, prostatic acid phosphatase was used for many years as “the most 
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valuable enzyme marker for the diagnosis of prostate cancer,” (p.52) because of its 
characteristic antigenic properties that are unlike other acid phosphatases (Lee, Li, Jou, 
et. al, 1982). Testosterone has also been theorized to have similar properties.  
All three markers (PSA, PAP, and testosterone) will be assayed in patient 
samples, some of which are cancerous and others which are not. The number of false 
positives and negatives and true positives and negatives will be calculated to determine 
the percent specificity and sensitivity of each test. The tests will then be compared by 
these means to determine which is the most accurate for the diagnosis of prostate cancer. 
The objective of this study is to compare the diagnostic efficacy of PAP with that of two 
other markers (PSA and testosterone). It is hypothesized that PAP will prove superior to 
PSA and testosterone for the diagnosis of prostate cancer.  
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Literature Review 
Cancer 
History 
 Cancer seems to be a disease of modern times. However, it actually has a lengthy 
recorded history. According to Harrington, Bristow, Hill, and Tannock (2005), even 
Egyptian mummies have been found with osteosarcomas. Ancient writings and pictures 
have been discovered that document cases of malignant tumors. Over the years, cancer 
has been attributed to many different causes. Hippocrates wrote that he believed cancer to 
be the result of an imbalance of the bodily “humors”: the black humor (from the spleen), 
blood, bile, and phlegm. The first acknowledgement of possible environmental causes of 
cancer occurred in the Middle Ages (Harrington, L., Bristow, R., Hill, R., Tannock, I., 
2005).  
 One of the most influential studies of cancer was published by Percivall Pott in 
1775. Pott studied the relationship between testicular cancer in chimney sweeps and the 
coal that remained on their skin due to infrequent bathing. As a result of his publication, a 
Danish worker’s guild began to advise bathing daily. By 1892, the incidence of cancer in 
that region had greatly decreased compared to others (Friedberg, E., 1985). Another 
implication of Pott’s study is the introduction of the idea that cancer can become 
malignant after a period of latency, that is, exposure to a carcinogenic agent or event may 
occur years before the production of a tumor. The chimney sweeps in the study were 
sweeps as young boys, but the cancer did not develop until years later (Harrington, L., 
Bristow, R., Hill, R., Tannock, I., 2005). Studies such as Pott’s firmly identified cancer as 
the result of environmental causes.  
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 In the nineteenth century, a scientist named Virchow observed the cellular nature 
of cancer. Virchow postulated that “every cell is born from another cell” (Harrington, L., 
Bristow, R., Hill, R., Tannock, I., 2005), true of both normal cells and cancerous ones. 
One notable aspect of cancer cells is their ability to continue growth beyond the point at 
which normal cells would cease proliferation. Cairns (1975) defined tumors as “groups of 
abnormally proliferating cells.”  
 Much of the recent study of cancer has focused on genetics and heredity. Studies 
that focus on this aspect must be performed on inbred populations, such as the Mormons 
of Utah. As a result, cancer has been recognized as a genetic disease. Not only that, but 
cancer has been associated both with inherited factors such as mutations of DNA and 
problems with DNA repair. Research into the genetics of cancer has also suggested that 
cancer is one disease with multiple causes as opposed to the old belief that each cancer 
represented a separate disease. Results have also shown that multiple changes in the 
genetic material are required for tumors to occur and the cell’s ability to respond to 
signals indicating mutations or lack thereof and consequent persistence of the mutation 
may be among the primary causes of cancer (Harrington, L., Bristow, R., Hill, R., 
Tannock, I., 2005). This and the recent discovery of the role of vascularization in the 
early stages of the proliferation of cancer cells has provided strength to arguments of 
proponents for treatments aimed at the molecular level of cancer.  
Epidemiology 
 McLaughlin and Gallinger (2005) define epidemiology as “the study of the 
distribution and determinants of disease in human populations.”(p.4). The International 
Agency for Research on Cancer’s (IARC) most recent statistics (2010) indicate that the 
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yearly incidence of cancer in the United States is 1,436,000, with 745,200 male cases and 
692,000 female cases. In that year there were 565,600 cancer deaths. The risk of 
contracting cancer before the age of 75 was calculated to be 33.5% for males and 26.7% 
for females (total 29.9%), and the risk of dying from cancer before age 75 is 12.8% for 
males and 9.8% for females (total 11.2%) (IARC, 2010). 
Major Types 
 The International Agency for Research on Cancer (IARC, 2010) determined the 
five most frequent cancers among both sexes to be lung, prostate, breast, colorectal, and 
bladder cancers. For women, the most frequent are breast, lung, colorectal, corpus uteri, 
and non-Hodgkin lymphoma cancers. For men, the top five are prostate, lung, colorectal, 
bladder, and non-Hodgkin lymphoma cancers. These statistics exclude non-melanoma 
skin cancers, which are typically the most frequent in both sexes.  
Lifestyle Choices 
 Rosenbaum (1983) stated, “We have control over 70-80% of the causes of 
cancers.” (p.8). Many lifestyle choices have been related to an increased risk of some 
cancers, such as smoking and lung cancers. Thirty-two percent of cancers are caused by 
smoking tobacco and 4% by excessive alcohol ingestion (Rosenbaum, 1983). Eighty-
seven percent of all lung cancers have been attributed to cigarette smoking, as well as 
30% of cancer deaths (Cook, 1996). Alcohol and smoking combined cause even more 
cancer. Alcohol disturbs the function of the immune system and increases the body’s 
susceptibility to illness and malignancies that cause cancer. It is considered a 
cocarcinogen that increases the tumor causing ability of other carcinogens (Rosenbaum, 
1983).  
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There is a well-established link between diets high in meat, sugar, and dairy 
products and increased incidence of breast cancer. Additionally, salted and pickled foods 
have been linked to stomach cancer in Japan. Overall, increased fat and caloric intake, 
obesity, meat consumption, and decrease in grains have been observed to correlate with 
high incidences of breast cancer, colon cancer, and uterine cancer (Rosenbaum, 1983). 
Even so, carcinogenesis is still a complex multistep process that depends on many other 
factors such as promoters, genetics, previous damage, and individual resistance.  
Oncogenes and Tumor Suppressor Genes 
 Basic knowledge of oncogenes and tumor suppressor genes is necessary to 
understand cancer on a molecular level, as these are the primary entities involved in 
carcinogenesis. All cancers have a genetic component whether somatic or inherited 
(Loescher, Whitesell, 2003). Oncogenes arise from proto-oncogenes that regulate cells’ 
signaling pathways. When a mutation occurs in a proto-oncogene that activates it to 
oncogene status, production of the protein produced by the transcription thereof is either 
increased or the protein itself is altered in structure or function (Hunt, 2005). These types 
of genes normally encode proteins that act to promote cellular proliferation by 
participating in signaling pathways that relay growth stimulating signals through cells 
and are essential to many normal cell functions. The complexity of the regulatory 
processes controlling the expression of proto-oncogenes has two implications for 
neoplastic (cancerous) cells: 1) the large number of components involved provides a large 
number of potential mutation targets, and 2) multiple regulatory pathways ensure that 
mutation/carcinogenesis must occur in multiple proto-oncogenes to be effective. Growth 
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factors and growth factor receptors are two types of oncogene products (Loescher, 
Whitesell, 2003).  
 Tumor suppressor genes are those whose protein products negatively regulate cell 
growth by blocking the action of growth promoting proteins (Loescher, Whitesell, 2003). 
Some have been seen to directly antagonize the action of proto-oncogenes in growth 
regulation (Fearon, 1998). Some of these genes are normally active transcription factors 
within the cell nucleus. Abnormal repression of tumor suppressor genes results in 
deregulation of the cell cycle (excess cellular proliferation by prolonging proliferation 
signals) or cellular disorganization (Loescher, Whitesell, 2003). Tumor suppressor genes 
require a germline mutation and a somatic mutation or two somatic mutations to initiate 
carcinogenesis (Hunt, 2005). This theory is referred to as Knudson’s Two-Hit Hypothesis 
and is based on Knudson’s study of the autosomal dominant inheritance witnessed in 
epidemiological studies of retinoblastoma (Fearon, 1998).  
Activation of multiple oncogenes and inactivation of several growth suppression 
genes is required for the acquisition of a completely neoplastic phenotype (Park, 1998). 
This is the result of the incorporation of oncogenes and tumor suppressor genes in 
signaling pathways and cellular regulation (Kalderon, 2000).  
Growth Factors, Receptors, and Signaling 
 Growth factors are protein products that stimulate cells in the resting state to enter 
the cell proliferative cycle in a process that occurs over several hours to ensure 
commitment to DNA synthesis by progression factors. The dual requirement of both a 
growth factor and a progression factor prevents accidental triggering of proliferation as a 
barrier to neoplasm. They can also promote or block differentiation in turn or along with 
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proliferation. Consequently, oncogenes derived from growth factor genes cause 
inappropriate expression of growth factors that cause ongoing stimulation of cell growth 
and blockage of differentiation (Park, 1998).  
 Growth factor receptors are an additional product whose derived oncogenes 
provide cells with the ability to proliferate without the requirement of growth factors 
(Park, 1998). Under normal circumstances, binding of a growth factor to its receptor 
initiates a signal that activates certain proteins and transmits a signal to the cell nucleus. 
The end result is a change in gene expression that ushers the cell through the growth 
cycle (Loescher, Whitesell, 2003). Different subtypes of growth factor receptors include 
tyrosine protein kinases, which regulate signal pathway events that affect cell shape and 
growth through phosphorylation of the amino acid tyrosine, cytoplasmic adaptor proteins, 
which relay signals from the cell surface to the nucleus by allowing further 
phosphorylation, proteins with GTP-ase activity, and cytoplasmic serine-threonine 
protein kinases whose expression is normally limited to germ cells (Park, 1998).  
 The interaction and regulation of such different protein products is controlled 
through the interplay of multiple signal proteins through signal transduction pathways. 
The resulting signals pass within and between cells to coordinate cellular decisions 
during development (Kalderon, 2000). Transduction changes the conformation of the 
affected protein and activates its enzymatic product, while generating sites for the 
recruitment of proteins targeted for further phosphorylation to transmit signals. The 
ultimate result is the generation of complexes of signal-transducing molecules at sites 
within the cell where they will then act on the carried signal (Park, 1998). Recall again 
that the complexity of these pathways performs a service in the prevention of 
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carcinogenesis, carrying two implications for tumors: 1) the large number of components 
involved provides a variety of potential targets for oncogene activation and 2) because of 
the consequent redundancy and cross-regulation within pathways, the conclusion follows 
that human cancers rarely result from aberrant activation of a single proto-oncogene 
(Loescher, Whitesell, 2003).  
Inheritance of Cancer 
Five to ten percent of cancers result from hereditary causes, usually from an 
autosomal dominant mechanism (gene is present on a non-sex chromosome and only one 
defective gene is required to cause neoplasm) with a 50% risk to offspring. Those passed 
through an autosomal recessive mechanism (non-sex chromosome, two defective genes 
required for neoplasm) cause a 25% risk to offspring (Hunt, 2005). On the genetic level, 
cancers often consist of chromosomal abnormalities such as gain, loss, or rearrangement 
of chromosomes, which are heritable. Heritable fragile sites (those sensitive to 
gaps/breaks) on chromosomes are also associated with cancers. They can result in 
translocation with damaged material, deletion, or amplification.  
However, although many cancers seem to be the result of inheritance, they are not 
a case of one single-gene inheritance and are not, as many believe, completely inevitable. 
Rather, it is the result of a multifactorial inheritance involving interaction of genes with 
the environment. Inheritance of certain genes simply increases one’s susceptibility and 
lowers the threshold of environmental hits required to produce a neoplastic phenotype. 
Susceptibility in cancers with a genetic component is increased in the following cases: a 
person with three or more close relatives affected by one or more types of cancer, cases 
in which at least two generations are affected, and in those involving young people 
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(Kelly, 1983). The majority of hereditary cancers are caused by mutations of tumor 
suppressor genes in germline cells (Hunt, 2005). 
Chemical Carcinogenesis 
 Chemical interference is another method of producing a neoplastic phenotype. 
Most chemicals require metabolic activation to become cytotoxic, mutagenic, or 
carcinogenic. The primary enzyme group involved in this process and conversely, in the 
process of detoxification is the microsomal monooxygenases or mixed function oxidases. 
They usually produce less harmful products but chemical interference can cause the 
production of more malicious, carcinogenic resultants. This interference can occur within 
intracellular regulation and biosynthesis leading to an increase or decrease of enzymatic 
activity, or by direct interference with the catalytic process. Another method of 
interference is inactivation or destruction of a key factor cytochrome in the detoxification 
process (Wiebel, 1980). Activation of such chemicals involves addition or alteration of 
the organic functional groups contained in the molecules and differs between each type of 
chemical carcinogen (Selkirk, 1980). Chemical carcinogens are typically electrophilic 
compounds which easily bind to DNA, causing bulky adducts which interfere with 
correct DNA replication and hence mutation.  
 After activation, chemicals can cause point mutations that subsequently activate 
proto-oncogenes and cause neoplasm (Park, 1998). However, there are a finite number of 
interactions at critical target sites that must occur to lead to tumorigenesis. In most cases, 
this is the result of a continuous bombardment of subthreshold doses of the chemical. The 
types of chemicals most known to cause cancer include polycyclic aromatic 
hydrocarbons such as coal tar, aromatic amines such as chemical dyes, nitrosamines and 
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nitrosamides such as alkyl urea, and aflatoxin, which is a mold that grows on food. Most 
of these predominantly cause liver tumors since chemicals are removed from circulation 
by the liver and metabolized, sometimes resulting in carcinogenic activation of the 
chemicals (Selkirk, 1980). Polycyclic compounds are capable of delocalization of charge 
and thus the maintenance of a very active electrophilic status.  
Radiation Carcinogenesis 
 Genetic insult from exposure to radiation can also initiate carcinogenesis. There 
are two major types of radiation: ionizing and non-ionizing. Ionizing radiation is that 
which has the capacity to accelerate electrons in matter (Tomatis, 1990). The movement 
of electrons in macromolecules of the body resulting from the ionizing effects of this type 
of radiation causes a change in the DNA structure and subsequent expression and 
function of the products encoded therein. This mechanism of alteration to the cellular 
DNA is most likely responsible for primary cellular effects and consequently 
carcinogenesis.(Ullrich, 1980).  
Exposure to ionizing radiation includes x-rays, gamma radiation from radioactive 
nuclides in the air, water, food, and minerals near the Earth’s surface, cosmic rays, and 
nuclear reactors. Cancer as a result of ionizing radiation was first seen in radiologists who 
developed hand carcinomas and in industrial workers who developed leukemias 20-30 
years after exposure to radiation. The effects of ionizing radiation were also investigated 
in survivors of the atomic bombs in Hiroshima and Nagasaki. An increased incidence of 
tumors was seen, accompanied by an increased risk to persons exposed in utero. Ionizing 
radiation has been seen to cause cancer in any organ in which cancer occurs naturally, 
though organs differ in rates of intrinsic susceptibility (Tomatis, 1990).  
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 The only form of non-ionizing radiation that has been evidenced to have 
carcinogenic properties is ultraviolet (UV) radiation, which has been connected to skin 
cancer. The two were first linked in 1896 and the connection was directly demonstrated 
in 1928 by exposing mice to a UV light. Wavelengths between 280 and 320 nanometers 
have shown to have the most carcinogenic capacity. However, a single dose is not 
sufficient to cause tumors, which only appear at the edges of severely damaged tissue 
(Ullrich, 1980). This suggests that many insults are required before tumorigenesis occurs. 
Although the mechanism of carcinogenesis by UV radiation is largely unknown, it has 
been shown that absorption of UV radiation results in electron excitation which may 
cause carcinogenesis in macromolecules. The formation of pyrimidine dimers, cross-
binding of bases in a strand of DNA left unrepaired by a damaged repair mechanism, has 
been the most studied means of carcinogenesis by UV radiation.  
Viral Carcinogenesis 
 The cellular changes that characterize cancers may also be acquired as a 
combination of environmental mutagens and infectious agents such as viruses. There are 
six known oncogenic viruses that have been associated with almost 20% of all human 
cancers. They are hepatitis B, hepatitis C, human papillomavirus, the Epstein-Barr virus, 
Kaposi’s sarcoma-associated herpesvirus, and human T-cell leukemia virus 1. Most 
oncogenic viruses cause carcinogenesis either by activating pre-existing oncogenes 
through insertion of a provirus into cellular chromosomes, encoding regulatory proteins 
to affect cell growth and death, or carrying an oncogene in their genome which has 
cellular homologues (Zheng, Ou, 2010). Some directly transform cells and are required 
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from that point forward to perpetuate the cancer, while others are only necessary during 
the initial stages of transformation (Tomatis, 1990).   
 Viral transformation is aided by the viruses’ ability to interfere in cellular 
communication through signal transduction. This interference is accomplished through 
viral proteins which mimic cellular signal ligands, signaling receptors, and intracellular 
signaling adaptors. This mimicry activates cell surface receptors and fools the cell into 
entering continuous proliferation while blocking cell death, thus deregulating the cell 
cycle to cause the neoplastic phenotype. 
 Chronic infections of hepatitis B and C viruses have been linked to hepatocellular 
carcinoma and liver disease while human papillomavirus is associated with cervical 
cancer and skin or genital warts. Epstein-Barr virus has been studied in great detail in 
association with malignancies such as gastric and nasopharyngeal carcinoma, Burkitt’s 
lymphoma, immunoblastic lymphoma, and T-cell lymphoma. Kaposi’s sarcoma-
associated herpesvirus is associated with its namesake, Kaposi’s sarcoma, which is a 
multifocal angioproliferative disorder that most often presents as a cutaneous lesion. 
Finally, human T-cell leukemia virus-1 is most often associated with adult T-cell 
leukemia, a malignancy with poor prognosis (Zheng, Ou, 2010).  
 Human immunodeficiency virus (HIV) lowers the body’s natural defenses by 
weakening the immune system and thus increases the risk of several types of cancer. 
Additionally, people with HIV often become infected with other viruses that also increase 
the risk of cancer, such as Epstein Barr Virus (EBV) and Human Papillomavirus (HPV). 
Those with HIV are at several thousand times higher risk of diagnosis with Kaposi’s 
sarcoma, and 70 times higher risk of diagnosis with non-Hodgkins lymphoma, compared 
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to those without HIV. Women with HIV are 5 times more likely to be diagnosed with 
cervical cancer as compared to women without HIV. Other cancers with increased risk to 
those with HIV include anal, liver, and lung cancer, and Hodgkins lymphoma. However, 
the recent introduction of highly active antiretroviral therapy has decreased the incidence 
of Kaposi’s sarcoma and non-Hodgkins lymphoma among people with HIV. This therapy 
acts by lowering the amount of HIV circulating in the bloodstream (National Cancer 
Institute, 2011).  
Cell Proliferation and Tumorigenesis 
 The products of proto-oncogenes have direct effects in the control of gene 
expression in normally proliferative cells as transcription factors. They perform this 
function until a loss of the negative regulatory regions, producing uncontrolled 
proliferation, or a loss of positive regulatory regions, resulting in a lack of expression of 
genes whose products are required for differentiation. These two events are both key to 
the neoplastic phenotype. Proto-oncogene products are also required for a cell to 
transition from the resting state to the beginning of the normal cell proliferation cycle and 
at certain points during the cycle (Park, 1998). 
 The cell cycle consists of five phases: G1, preparation for DNA synthesis; S, 
DNA synthesis; G2, preparation for mitosis; M, cell division; and G0, the resting state. A 
number of mitogenic signals regulate these interconnected phases in a system that is 
cross-linked and double-checked (Nakamura, 1997). Normal cells have a limited 
propagation potential that averages 60-70 cell divisions. After this point, cells become 
senescent unless (as in carcinogenesis) loss of tumor suppressor genes confers additional 
replicative capacities. In this case, the cells eventually enter a state of crisis including 
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massive apoptosis and joining of chromosomes. Normally, propagation is limited by a 
sequence at the ends of chromosomes called a telomere which is shortened with each cell 
division. At a certain point when the telomere is gone, the cell can no longer divide 
because it begins to lose DNA from the ends of the chromosomes instead. However, an 
enzyme called telomerase can replace the telomeres and is expressed in low levels in 
healthy cells. Reactivation of this enzyme is seen frequently in malignantly transformed 
cells. The telomere may also be maintained by an alternative recombination-based 
mechanism. These two mechanisms are the main ones by which cancer cells attain an 
infinite multiplication potential (Zheng, Ou, 2010).  
 Genetic instability is one of the main characteristics of tumorigenesis and the 
resulting cancer, and is caused by gene mutations, microsatellite instability, or 
chromosomal instability. Accumulation of many of these genetic alterations in the 
genome is required for the multistep process of tumorigenesis and the continued 
progression of tumors. Healthy cells have a variety of protection mechanisms for 
genomic integrity such as highly accurate DNA polymerases to reduce error during 
replication, mechanisms employed to monitor DNA damage and restore damaged 
information (such as base excision repair), and mitotic checkpoints during the cell cycle 
to analyze abnormalities produced during mitosis or chromosomal segregation (Zheng, 
Ou, 2010).  
Tumor Progression and Metastasis  
 Approximately 30% of new cancer patients with solid tumors have evident 
metastases. Metastases are the main cause of cancer deaths and the definition of 
malignant cancers. A “benign” tumor is one which is localized and amenable to local 
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surgical removal and resulting survival of the patient. Tumors become “malignant” when 
they invade and destroy adjacent organs and/or spread to distant sites. Malignancy is also 
characterized by a spread from one organ to another that is not directly adjacent to it. 
Dissemination of a tumor greatly decreases the possibility of a cure, if not prevents it 
entirely (Bani, Gaivazzi, 2000).  
 There are several mechanisms of metastatic spread of tumor cells which differ 
between types of cancers. Cells may invade a nearby natural body cavity, use the lymph 
fluid as an enhancement of motility, or use a hematogenous means. Carcinomas typically 
spread lymphatically, while sarcomas spread hematogenously. Due to numerous 
interconnections of all systems, most cancers use both of these most common routes. For 
example, a group of tumor cells may travel through the lymph nodes to reach the vascular 
compartments. However, all metastases progress through the same series of steps which 
may occur at the same time or in a series. First, a group of cells detaches from the solid 
tumor mass, invades the surrounding healthy tissue, and intravasates to the vascular 
channels. The cells must then survive as a clump or reduce to a single cell in the 
circulation before stopping in the capillary bed of a new site. Next the cell or cells 
extravasate through the vessel wall and infiltrate the surrounding tissue compartment 
before growing into a new solid tumor. During the whole process, the tumor cells have to 
evade constant immunologic surveillance, fail to respond to growth control factors, and 
promote angiogenesis (Bani, Giavazzi, 2000).  
 Malignant tumor progression is marked by the accumulation of genetic alterations 
which leads to permanent phenotypic changes, and is perpetuated more efficiently 
through metastasis (Bani, Giavazzi, 2000).   
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Angiogenesis 
 “Angiogenesis is the formation of new blood vessels from the existing vascular 
bed.” (Piulats, Mitjans, 2000, p.271) In healthy (non-cancerous) body environments, 
angiogenesis is found in wound healing and in endometrium vascularization during the 
menstrual cycle, but it is also a key component of cancers (Piulats, Mitjans, 2000). A 
tumor may only grow so large until nutrients and blood can no longer reach the innermost 
cells by diffusion. New blood vessels must be produced to carry them to the central cells 
of the tumor mass.  
 According to Piulats and Mitjans (2000), neovascularization begins when the 
tumor grows larger than one millimeter cubed and is carried out by the extracellular 
matrix and endothelial cells when the tumor cells secrete angiogenic factors to attract 
endothelial cells. Similar angiogenic factors such as angiostatin and thrombospondin 
regulate the response in healthy environments. The first endothelial cells at the site 
become activated and produce paracrine growth factors for the tumor that increase tumor 
growth and angiogenic potential. This cross-communication between endothelial cells 
and tumor cells is one of the hallmarks of angiogenesis. Another hallmark is a precarious 
equilibrium between inducers and inhibitors of neovascularization, which is affected 
towards the inducement end of the spectrum by the effect of tumor cells to promote 
inducers such as transforming growth factor beta and platelet-derived endothelial growth 
factor (Piulats, Mitjans, 2000).  
 The three defined steps of angiogenesis are induction-initiation, proliferation-
invasion, and maturation-remodeling. The initiatory step of angiogenesis, induction, is 
characterized by the release of inducers such as growth factors or cytokines both from 
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tumor cells and other cells recruited to the area. Proliferation-invasion involves a 
promotion of blood vessel growth in the direction of the tumor mass. Changes in cell 
adhesion are made that allow interaction of endothelial cells with the surrounding 
environment to promote angiogenesis and cell survival. Finally, maturation-remodeling 
consists of stopped proliferation and the beginning of differentiation of vessel walls and 
lumen (inner vascular space) formation followed by blood circulation to the tumor mass 
(Piulats, Mitjans, 2000).  
 Angiogenesis indicates a particularly advanced stage of disease. Therefore, 
knowledge about the process retains both prognostic and therapeutic value.  
Apoptosis 
 Apoptosis is programmed cell death that usually occurs as a result of a cellular 
process involving both biochemical and morphological changes. It is often a response to 
extensively damaged DNA and allows for removal of old, dead, or nonfunctional cells 
(Loescher, Whitesell, 2003). Apoptosis is unique because it is the result of an inherent, 
regulated pathway that is a part of all cells of the body and not the result of trauma or 
external factors as in necrotic cell death. It also does not result in the release of cytokines 
or any inflammatory response (Rudin, Thompson, 1998). Characteristic morphologic 
marks of apoptosis include condensation of nuclear material, cytoplasmic condensation 
resulting in cellular contraction and loss of adhesion, and an irregular cell surface with 
protrusions that round up and break away (Archer, Trott, Dowsett, 2000). This process is 
highly regulated and a key part of inhibition of carcinogenesis (Rudin, Thompson, 1998). 
 Conversely, escape of apoptosis is also a key component of the progression of a 
neoplastic phenotype. For example, the cell cycle may become deregulated resulting in 
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uncontrolled proliferation but unless apoptosis is controlled, offending cells may be 
destroyed before progression can occur. Apoptosis is initiated by both intra- and 
extracellular signals including DNA damage (intracellular) and tumor necrosis factor-
alpha (extracellular). Signal transduction occurs throughout the cell, culminating at the 
mitochondria where cytochrome c is released. This product activates a group of enzymes 
called caspases that initiate a cascade to perpetuate cell death signals to different cellular 
components, causing their disintegration. Mutations in genes involved in either the 
signaling or the consequent cascade can result in escape from apoptosis (Zheng, Ou, 
2010).  
Tumor Markers 
 Tumor markers are abnormal molecules or processes whose presence indicates a 
change in cellular environment to malignancy. They have great prognostic value because 
they allow medical personnel to differentiate a large population of cancerous individuals 
into subpopulations based on stages of increasing malignancy and differing in prognosis. 
They can also be used to predict which therapies are likely to have the best effect on a 
patient. Use of such markers can prevent the unnecessary treatment (e.g. potentially toxic 
exposure to drugs) of non-cancerous individuals exhibiting similar symptoms. Markers 
can include changes at the genetic level (mutations), the transcriptional level 
(over/underexpression), the translational level (increased/decreased level of product), or 
the functional level (presence of neovascularization). They can be assessed using various 
clinical methods and assays. The American Society of Clinical Oncology tests and 
approves various tumor markers through a rigorous method and consequently 
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recommends very few for analysis based on their sensitivities and specificities (Hayes, 
2000).  
 An important tumor marker is TP53, derived from the p53 gene proteins. The p53 
gene is integral to many cell processes and is highly conserved. Mutations thereof and 
subsequent production of TP53 are associated with almost all tumor types, especially 
colorectal carcinoma, and carcinomas of the breast, lung, esophagus, stomach, liver, and 
bladder. TP53 is an important marker predictive of poor prognosis, increased risk of 
relapse and cancer death risk, though this prognostic use is controversial. RAS is another 
group of highly conserved genes involved with cellular proliferation and homologous to 
several viral oncogenes. Mutations of RAS produce continuous signals leading to 
malignant transformation and are associated with cancers such as adenocarcinoma of the 
pancreas, colon cancer, and lung cancer. MYC is a marker whose cellular version has 
been isolated from neuroblastoma and small-cell lung cancer. It encodes for nuclear 
DNA-binding proteins involved in the regulation of transcription and is involved in 
control of proliferation, transformation, differentiation, and inducement of apoptosis. 
Other notable genetic markers include HER-2, RET, BCL2, BCL1-PRAD1-CCND1, 
REL, and BCL-6 (Birindelli, Aiello, Lavarino, et. al, 2000).  
 Tumor markers also include those derived from chromosomal or DNA-level 
instability. Microsatellites, or simple sequence repeats, can be detected by increased 
incidence. MSI are errors that occur in microsatellite sequences during replication and 
produce expanded or shortened sequences that cause cellular confusion issues. Loss of 
heterozygosity reflects mutations that cause a loss of function in tumor suppressor genes. 
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Loss of heterozygosity also has value as an early diagnosis marker and later as a 
prognostic and therapeutic response marker (Birindelli, Aiello, Lavarino, et. al, 2000).  
Prostate Cancer 
Epidemiology 
Prostate cancer has been determined to be the most frequent cancer in men, 
representing about 30% of all male cancer cases, excluding non-melanoma skin cancers 
(IARC, 2010). In 2004, there were an estimated 230,110 diagnoses and 29,900 deaths due 
to prostate cancer in the United States. Risk factors include increased age, family history 
or genetics, African-American ethnicity, hormone levels, and increased serum level of 
prostate specific antigen (PSA). Ninety-five percent of total cases occur in men ages 45 
and older with a dramatic increase in incidence at the age of 55 (Stratton, S., Ahmann, F., 
2005). Less than 1% of prostate cancer cases occur in males less than 40 years of age and 
the peak frequency of 1 in 7 occurs in men in their 80s and 90s (Isaacs, Bova, 1998).  
Prostate cancer has proven to be one cancer which has an appreciable genetic 
component. Five to ten percent of prostate cancers are thought to be attributable to the 
inheritance of certain alleles that increase susceptibility (Isaacs, Bova, 1998). Genetic 
study has even gone so far as to link the appearance of prostate cancer with specific 
anomalies on chromosomes eight and ten (Stratton, Ahmann, 2005).  
Ethnicity is also a risk factor for prostate cancer. African American men have the 
highest incidence (32% more than American white males) and mortality rate. The 
increased mortality rate may also be due to the fact that African-American males are 25% 
less likely to undergo regular prostate screenings. (Stratton, S., Ahmann, F., 2005). 
Prostate cancer has shown to be uncommon in Asian males and alternatively high in 
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Scandinavian countries, such as Finland (Isaacs, Bova, 1998). There has recently been a 
rise in the incidence of prostate cancer in Japan, thought to be the result of the appearance 
of a more Westernized diet and lifestyle in the East in conjunction with increased 
exposure to environmental contaminants. Because of the increase in incidence with age, 
there is a higher incidence in developed countries with a longer life expectancy. Prostate 
cancer accounts for about 4% of male cancer in developing countries, as opposed to 15% 
in developed countries. The epidemiology suggests a combination of environmental and 
genetic causes (Stratton, S., Ahmann, F., 2005).   
Signs and Symptoms 
 The signs and symptoms of prostate cancer are somewhat vague and indistinct 
and as a consequence, cases of prostate cancer are often asymptomatic and unexpectedly 
diagnosed as the result of a regular screening test (Bostwick, MacLennan, Larson, 1996). 
Signs and symptoms can include weak or interrupted urine flow, inability to urinate, 
difficulty starting or stopping urine flow, need to urinate frequently, especially at night, 
blood in the urine, pain or burning on urination, and continuing pain in the lower back, 
pelvis, or upper thighs (Cook, 1996). Other nonspecific symptoms can include a loss of 
appetite or weight loss (Bostwick, MacLennan, Larson, 1996).  
Diagnosis and Staging 
 Diagnosis of prostate cancer is performed using a full medical history and a 
complete physical, followed by certain specific prostate tests. A rectal exam is often 
performed, in which a physician inserts a gloved finger into the rectum to palpate the 
prostate for hard or lumpy regions that could prove to be tumorous. A prostate specific 
antigen (PSA) test is also performed on a sample of the patient’s serum. Both prostate 
  24 
cancer and benign prostatic hyperplasia (a non-cancerous condition associated with 
excess prostate growth) are accompanied by an increase in serum PSA. A test for 
prostatic acid phosphatase (PAP) is also sometimes performed; as PAP rises are seen in 
many prostate cancer patients, especially if the condition includes metastases of the 
tumor. Other tests include transrectal ultrasonography, in which a probe inserted in the 
rectum emits sound waves to produce a sonogram of the prostate; an IV pyelogram, 
which produces x-rays of the organs of the urinary tract to search for tumors causing 
pressure to the area; and urine tests for hormone levels and blood. A biopsy is often 
performed later in the diagnosis to confirm the cancerous nature of a suspected tumor 
mass (Cook, 1996).  
 After diagnosis, patients are classified by their tumor’s grade and stage. Grading 
is based on the differentiation state of the tumor cells and is determined by the 
appearance of extracted cells viewed under a microscope. The tumor is then graded by 
the Gleason system with a number from one to five, with one being well-differentiated 
and five being undifferentiated. Staging concerns the extent of the cancer in the patient, 
how large it is, whether it has spread beyond the prostate, and if so, how far. Staging is 
complex and combines multiple testing parameters such as rectal exam results, PSA 
level, estimated tumor volume, and other tests. The tumor is then staged based on the 
tumor, node, metastases (TNM) system. The scale starts with T0 which goes to T4, then 
moves up to N0 to N3, then to M0 and M1. The T portion of the scale describes the 
extent of the primary tumor, which is the only mass present at that point. The N portion 
describes the appearance and state of pelvic area lymph nodes (often the first site of 
metastasis). Finally, the M portion of the scale indicates the presence or absence of 
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distant metastases. The numbers increase with the relative seriousness of each portion of 
the scale and the number 0 by a letter indicates that there is no evidence of that parameter 
(Bostwick, MacLennan, Larson, 1996).  
Treatment 
 The choice of therapy generally depends on the patient’s age and the stage of the 
tumor, as there are several methods to choose from. Surgery is an ideal choice if the 
cancer has not spread from the primary tumor. A radical prostatectomy consists of the 
removal of the prostate and some of the surrounding tissue and is often preceded by a 
dissection of the pelvic lymph nodes to ensure they contain no cancer. Side effects 
include impotence and leakage of urine from the bladder. A transurethral resection is also 
an option to cut the cancer from the prostate and is often used to relieve symptoms. 
Cryosurgery has become an option in recent times to kill the cancer by freezing it (Cook, 
1996).  
 Radiation therapy is a local treatment option in which high energy rays damage 
the DNA of the cancer cells and prevent them from dividing. The patient’s normal cells 
are also affected, but have a greater capacity to recover from the effects. Radiation also 
works best early on when the cancer is still confined. It is also used in conjunction with 
hormone therapy or after surgery to destroy remaining cancerous tissue. Radiation 
therapy is accomplished with external devices or internally implanted pellets (Bostwick, 
MacLennan, Larson, 1996).  
 Hormone therapy is a systemic treatment option to prevent the cancer cells from 
receiving the male hormones they require to grow, such as testosterone. It mainly 
controls the tumor and alleviates symptoms (Bostwick, MacLennan, Larson, 1996). 
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Removal of the testicles eliminates a source of testosterone, while administration of 
estrogen stops its production. However, the adrenal glands still produce small amounts of 
male hormones and side effects include growth of breast tissue, hot flashes, loss of sexual 
desire, impotence, nausea, and vomiting. This therapy cannot work indefinitely. 
Eventually, the tumor cells gain the ability to continue growth without the presence of 
testosterone (Cook, 1996).  
 The final treatment option is chemotherapy, or the administration of drugs to kill 
cancer cells. They may be taken in pill form or injected directly into the bloodstream or 
prostate. Thus far chemotherapy has had little significant effect on prostate cancer (Cook, 
1996).  
Markers of Prostate Cancer 
 Molecular markers of prostate cancer include oncogenes, tumor suppressors, 
proteins involved with inflammation, and serum proteins that usually increase in relation 
to prostate cancer. Androgens such as testosterone and 5α-dihydrotestosterone are 
involved in male sexual differentiation and are associated with prostate cancer. Androgen 
receptor polymorphisms such as trinucleotide repeats and single nucleotide 
polymorphisms are related to variations in prostate cancer risk. Nuclear factor κB is 
frequently overexpressed and activated in prostate carcinomas. Interleukin-6, 
cyclooxygenase-2, and B-cell lymphoma/leukemia-2 are also important indicators 
involved in processes surrounding the development of prostate cancer such as 
inflammation and apoptosis (Stratton, Ahmann, 2005).  
 Prostate specific antigen (PSA) is the primary marker screened for in potential 
cases of prostate cancer and is so far the most accurate indicator thereof. PSA is a serine 
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protease with strong substrate specificity and is normally secreted by the prostate in large 
amounts into the seminal fluid. The normal level of PSA in the blood stream is 4 ng/mL, 
though this fluctuates with age. The level dramatically increases with the development of 
prostate carcinoma and is a reliable determinant of the progression of the disease. It is 
often assayed after treatment to assess the function of the remaining prostate and possible 
presence of remaining cancer cells (Isaacs, Bova, 1998).  
 PSA is produced by the prostatic epithelium and functions in liquefaction of the 
seminal coagulum. Incidence of an elevated serum level increases with the stage of the 
tumor. Elevated amounts are found in both prostate cancer and benign prostatic 
conditions and falsely elevated amounts can be caused by a rectal examination. 
Additionally, not all prostate cancer cases are associated with levels above the normal 
range, with 20% of tumors accompanied by a normal level. However, in those with 
elevated content, the rate of increase can distinguish between patients with local or 
regional disease and those with advanced metastatic disease. A decrease after treatment 
indicates a patient with a good prognosis in remission and changing levels can indicate 
whether post-therapy irradiation is necessary (Horwich, Ross, 2000). 
 Levels of PSA between 4.0 and 10.0 ng/mL are associated with a diagnostically 
vague range of conditions, as levels caused by benign prostatic hyperplasia and prostate 
cancer mostly overlap. With a biopsy at this stage, 75% of men would prove to have no 
evidence of malignancy. PSA levels above 10.0 ng/mL indicate a 40-50% chance of 
prostate cancer and biopsies are frequently performed on men with serum levels above 
this point. The likelihood of an organ-confined malignancy is as low as 25% (Haese, 
Becker, Diamandis, et. al 2002).  
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 Testosterone is a steroid hormone whose measurements are useful in evaluating 
the hypogonadal states. High levels of testosterone are associated with hypothalamic 
pituitary unit diseases, testicular tumors, congenital adrenal hyperplasia, and prostate 
cancer (Diagnostic Automation, Inc., 2001). Testosterone is the most important form of 
androgen and 95% is produced by the testicles. It is a requirement for prostate growth and 
male virilization. Because of the effect of testosterone on growing prostate cells, it also 
fuels the growth of prostate cancer cells and is required for the continued growth of the 
tumor mass (Bostwick, MacLennan, Larson, 1996). Consequently, the conclusion has 
been reached that an increased mass of prostate tissue, as caused by a tumor growth, 
would be accompanied by a rise in testosterone levels. Thus, it follows that an assay for 
the levels of testosterone in a patient suspected of having prostate cancer might indicate 
the presence of a tumor and possibly the tumor’s size.  
 The first tumor marker used for prostate cancer was prostatic acid phosphatase 
(PAP). Acid phosphatases are a family of proteins found in many different tissues and 
whose isoenzymes have many different properties. PAP is mainly composed of two of 
these isoenzymes which are found in the prostate as well as the granulocytes and the 
pancreas. Consequently, levels of PAP may be elevated in a variety of conditions such as 
polycythemia rubra vera, granulocytic leukemia, Gaucher’s disease, pancreatic cancer, as 
well as prostate cancer. PAP is produced by epithelial cells lining the prostatic acini and 
is found in high concentrations in prostatic fluid in healthy patients and in the serum of 
more than 75% of patients with metastatic prostate cancer. However, PAP tests have been 
shown to have relatively low sensitivity and specificity in the diagnosis of prostate cancer 
and were replaced by the PSA screening test (Horwich, Ross, 2000).  
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 In recent times, PAP has mainly been used to monitor response to therapeutic 
approaches and determine patients’ clinical status. Increasing levels correlate with 
increased progression of the disease and with metastasis. (Wu, 1997). PAP levels are also 
utilized in making therapeutic decisions such as predicting the efficacy of surgery on a 
particular patient. Some rare tumors may not produce PSA, in which case PAP is used as 
the primary tumor marker to assess their condition. PAP has also been reported to have 
predictive value in determining which patients are most likely to have recurrences of their 
cancer and when to expect long term failure. In these cases, PAP was reported to have 
more value than Gleason score or PSA level (Haese, Becker, Diamandis, et. al, 2002).  
Prostate Cancer Assays 
 Assays for markers of prostate cancer are accomplished by incubating a patient 
serum sample with various reagents and colorimetric indicators in microwell plates with 
antibodies to a particular marker embedded in its walls. The marker attaches to the 
antibody and unbound antigen is washed away. The intensity of the color produced is 
dependent upon the amount of marker-antibody complex and is indicative of the 
concentration of the tumor marker. The intensity is quantitated by its absorbance using 
spectrophotometric methods.  
For assays to be used in the diagnosis of patients, both high specificity and 
sensitivity are desired. An antibody should be chosen which has a high affinity for 
binding to the marker to be tested to increase the sensitivity, and exclusive binding to the 
specific marker to increase the specificity. The use of monoclonal antibodies also 
increases specificity by exclusively binding to one epitope of a tumor marker, as opposed 
to polyclonal antibodies which bind to any of a number of epitopes which may be shared 
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by several different tumor markers. The most popular test format is a sandwich format 
enzyme-linked immunosorbent assay (ELISA), in which a specific antibody is absorbed 
in the solid phase on the walls of a microwell plate. A sample of serum is added and the 
antigen (the tumor marker) is allowed to bind during an incubation period in the presence 
of a reagent. The solution is washed and any unbound antibody is washed away. The 
solid phase contains the tumor marker “sandwiched” between the solid phase capture 
antibody and the added indicator antibody. An enzyme substrate is added which produces 
a colorimetric reaction whose intensity is directly proportional to the concentration of the 
tumor marker in the original sample. The other popular test method involves the principle 
of competitive binding, in which antigen (tumor marker) in the sample competes with a 
determinate amount of radioactively labeled antigen for binding with the antibody. The 
complexed antigen is separated from the free antigen and the amount of radioactivity is 
used to determine the concentration of antigen in the original sample (Wu, 1997).   
PSA is typically measured by radioimmunoassay. Sensitivity and specificity may 
be increased by refining the assay’s parameters to include PSA density, velocity, and 
relativity to age, fractionation, and measurement of cells in the circulation expressing 
PSA mRNA. (Horwich, Ross, 2000). PAP is measured using electroimmunoassay using 
monoclonal antibodies (Wu, J., 1997).  Testosterone is measured using 
electroimmunoassay based on the principle of competitive binding (Diagnostic 
Automation, Inc., 2001).  
A normal reference interval (NRI) is determined by sampling a large range of the 
population and plotting the results on a graph of frequency versus concentration. The 
mean of the set of values plus and minus two standard deviations is usually accepted as 
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the range of healthy patient values as this range covers 95% of healthy people. These 
ranges are used in making diagnoses to determine the disease states of patients and the 
extent of their conditions. They vary by analyte, gender, age, and test method.  The 
normal range for PSA is less than 4 ng/mL and for PAP, less than 5 ng/mL. For men 
under 50, the range for testosterone is 2.9-13 ng/mL and for men over 50 it is 1.8-7.5 
ng/mL.  
This study will examine the efficacy of tests for PAP and testosterone in 
comparison with the current standard PSA in the diagnosis of prostate cancer. It is 
designed to determine the percent sensitivity and specificity of each test based on 
calculations using the number of false positives and negatives; and true positives and 
negatives of each test. The sensitivities and specificities will be compared to determine 
the most accurate test. Finally, predictive values will be determined on all three markers 
as a whole to evaluate their use together. This study is executed on the hypothesis that 
PAP was discarded too early in its use as a guide to the diagnosis of prostate cancer and 
that present test methods provide a more accurate quantitation of its concentration, 
making it a better indicator of the presence of prostate cancer.  
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Materials and Methods 
Materials 
 The kits used in this project were acquired from Diagnostic Automation, Inc. 
(Calabasas, CA). All solutions utilized were prepared using diluents present in the kits. 
Tests were performed using immunoassays for prostatic acid phosphatase and 
testosterone. Statistical analyses were performed using SPSS version 18 statistical 
software. The samples were tested for prostate specific antigen at the hospitals of their 
origin. Permission for this study was granted by the University of Southern Mississippi 
Institutional Review Board under the protocol number 11080903 in accordance with 
Federal Drug Administration regulations, Department of Health and Human Services, and 
university guidelines to ensure adherence to stipulated criteria.   
 Patient serum samples were obtained from Memorial Hospital at Gulfport 
(Gulfport, MS) and Singing River Hospital (Pascagoula, MS) with only a patient number 
and the cancer diagnosis provided. Normal samples, obtained from Wilford Hall Medical 
Center (U.S. Air Force Base in San Antonio, TX) and Forrest General Hospital 
(Hattiesburg, MS), were also utilized from persons not suspected of having cancer to 
provide a basis of comparison. All procedures detailing the confidentiality of patient 
medical records were followed and no information regarding the identification of a 
specific patient was released by the hospitals involved. Aseptic techniques were used at 
all times with the samples. Samples were collected by hospital personnel at the respective 
hospitals, allowed to clot, and centrifuged before being frozen and packaged in plastic 
tubes for transport. Before testing, all samples were sorted into test tube racks and 
  33 
allowed to reach room temperature by soaking in a low level water bath at approximately 
25°C.  
 Patient samples were classified by the hospital pathologists as either cancerous or 
cancer free (Table 1). This diagnosis was provided for comparison only. One hundred 
two normal control samples (from males in good health) were tested without bias in order 
to generate a normal (healthy) interval for reference.  
Three test procedures were used in this experiment and consequently three sets of 
materials were required. The results of the assays performed in the laboratory were read 
with a Beckman Coulter AD 340 microplate reader. The washing of the micro-well 
solutions was done with a Stat Fax 2600 microplate washer. The assays performed at the 
provider hospitals were done with a Beckman Coulter Synchron LXI 725/Beckman 
Access process. 
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Table 1 
Test Sample Classification 
Number of Samples Cancer Diagnosis 
82 Cancerous 
469 Cancer free 
Total patients evaluated: 551 
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Prostatic Acid Phosphatase kit 
 The kits catalog #42272 and lot #12301054 used for this procedure came from 
Diagnostic Automation, Inc. Materials that were required and not provided with the kits 
include disposal tips, pipettors of 25 µL and 100 µL, a microwell reader, and deionized 
water for use as blanks.  
 The prostatic acid phosphatase (PAP) kit used is a quantitative solid phase 
enzyme linked immunosorbent assay with a detection range of 0-30 µg/mL. The test 
requires 50 µL of serum and performs to a specificity of 96% at a sensitivity of 1 µg/mL 
(as recorded by Diagnostic Automation, Inc.). The wells provided are coated with anti-
PAP antibodies and the enzyme conjugate is a mixture of anti-PAP antibodies chemically 
conjugated to horseradish peroxidase. The antibodies in the conjugate have different 
affinities toward epitopes of PAP molecules. The conjugate binds to the sample mixture 
in an amount proportional to the amount of PAP in the sample. Washing the solutions 
with the wash buffer removes any unbound conjugate. After addition of the TMB 
solution, a colorimetric reaction occurs whose final color intensity is proportional to the 
bound enzyme conjugate and thus the concentration of PAP present (Diagnostic 
Automation, 2010). 
In preparation for the assay, all reagents and samples were brought to room 
temperature (24±3°C) and gently mixed. The kit components, reagents and samples were 
unpackaged and placed in the work space. The wash buffer was prepared by adding 10 
mL washing buffer concentrate into 990 mL distilled water in a large flask. The mixture 
was capped and inverted several times before pouring into the wash solution bottle. 
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Blanks (deionized water), calibration solutions, and controls (calibration solution 
of 3 ng/mL was used as the control) were run in duplicate in the first 14 wells of each kit. 
The remaining wells contained serum samples or extra controls. A data sheet was kept to 
identify samples, calibrators, and controls with their respective well locations. New pipet 
tips were used for each dispensation. The procedure in figure 1 was followed.  
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Figure 1  
Prostatic Acid Phosphatase Immunoassay Kit Procedure 
1. Secure the wells in the holder.  
2. Bring all reagents and samples to room temperature and mix gently.  
3. Dispense 25 µL of references, controls, or serum samples into the appropriate 
wells.  
4. Dispense 100 µL of enzyme conjugate into wells.  
5. Incubate for 30 minutes at room temperature.  
6. Remove incubation mixture. 
7. Rinse the wells 5 times with washing buffer (300µL/well/each rinse).  
8. Dispense 100 µL of TMB solution into each well.  
9. Incubate for 15 minutes at room temperature.  
10. Stop reaction by adding 50 µL of stop solution into each well.  
11. Read O.D. at 450 nm with a microwell reader within 5 minutes.  
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Testosterone kit 
 The kits catalog #RN-42074 and lot #RN-42010 used in this procedure came from 
Diagnostic Automation, Inc. Materials required for the assay and not provided with the 
kits include disposable tips and pipettors of 10 µL, 50 µL, 100 µL, and 1.0 mL, deionized 
water, and a microwell reader.  
 The testosterone kit used is an enzyme immunoassay intended to quantitatively 
determine the concentration of testosterone in human serum. Diagnostic Automation, Inc. 
recorded its sensitivity to 0.05 ng/mL. The assay requires 10 µL of serum. Samples are 
dispensed into anti-rabbit IgG-coated wells and incubated with testosterone-HRP 
conjugate and rabbit anti-testosterone. The testosterone-HRP (fixed, known amount) 
competes with the testosterone in the sample to bind to the testosterone antibody (with a 
fixed number of binding sites). Unbound testosterone is washed away. Consequently, the 
detectable amount of testosterone-HRP bound to the wells decreases as the amount of 
testosterone in the sample increases. The TMB reagent added to the solution produces a 
colorimetric reaction which is then stopped by the addition of the stop solution. The 
intensity of the color produced can be measured spectrophotometrically to determine the 
amount of enzyme bound to the wells, which has an inversely proportional relationship to 
the concentration of testosterone in the samples (Diagnostic Automation, Inc., 2001).  
 In preparation for the assay, all reagents and samples were brought to room 
temperature (24±3°C) and gently mixed. The kit components, reagents and samples were 
unpackaged and placed in the work space.  
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 References, controls, and serum samples were run in duplicate at the beginning of 
each procedure. A data sheet was recorded with the identification of samples, references, 
and controls and their well numbers. The procedure in figure 2 was followed.  
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Figure 2  
Testosterone Immunoassay Kit Procedure 
1. Secure the coated wells in the holder.  
2. Dispense 10 µL of standards, specimens, and controls into appropriate wells.  
3. Dispense 100 µL of testosterone-HRP conjugate reagent into each well.  
4. Dispense 50 µL of rabbit anti-testosterone reagent into each well.  
5. Thoroughly mix for 30 seconds.  
6. Incubate at 37°C for 90 minutes.  
7. Rinse and flick the microwells 5 times with distilled or deionized water.  
8. Dispense 100 µL of TMB reagent into each well.  
9. Gently mix for 5 seconds.  
10. Incubate at room temperature (18-25°C) for 20 minutes.  
11. Stop the reaction by adding 100 µL of stop solution to each well.  
12. Gently mix 30 seconds until all the blue color turns to yellow.  
13. Read absorbance at 450 nm with a microwell reader within 15 minutes.  
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Prostate-Specific Antigen test  
 This assay was performed in the hospital laboratories where the patient samples 
originated. The reagent kits came from Siemens Healthcare Diagnostics with the catalog 
name ADVIA Centaur Assay. 
 This PSA assay procedure has been labeled a “two-site sandwich immunoassay” 
(Siemens, 2009) because of its use of two antibodies that “sandwich” the antigen. 
Constant amounts of both antibodies are used. The first antibody (a polyclonal goat anti-
PSA antibody) is labeled with acridium ester, while the second (a monoclonal mouse 
anti-PSA antibody) has been linked to paramagnetic particles. The combination of these 
antibodies with the antigen (PSA) leads to a chemiluminescent reaction that can be 
measured in relative light units (RLUs). The amount of RLUs expressed is in direct 
correlation with the amount of PSA present in the patient sample. This test requires 35µL 
of serum and is performed automatically by the ADVIA Centaur system.  
 In preparation for the assay, all reagents and samples were brought to room 
temperature (24±3°C) and gently mixed. The kit components, reagents and samples were 
unpackaged and placed in the work space. The procedure in Figure 3 was followed.  
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Figure 3  
Prostate Specific Antigen Procedure 
1. Prepare the specimen container for each specimen, and place barcode labels on 
the specimen containers, as required.  
2. Load each specimen container into a rack, ensuring that the barcode labels are 
clearly visible.  
3. Place the racks in the entry queue.  
4. Ensure that the assay reagents are loaded.  
5. Start the entry queue if required.  
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Results 
Over the course of the project, quality control samples were incorporated into the 
assays to determine within- and between-run precision (Table 2). For the PAP assays, the 
calibrators provided were used, and additionally the provided 3 ng/mL calibrator was 
used as a control. For the testosterone assays, the calibrators and controls provided 
(control 1=0.486-1.5 ng/mL, control 2=5.2-14.0 ng/mL) were utilized. The coefficient of 
variation (%CV) for PSA was low (2%), but those for PAP and testosterone (41.78% and 
23.29%, 10.74%, respectively) varied a great deal. Serial dilutions of patient samples 
were used to determine the linearity of the assays (Table 3, Graphs 1-3). These results 
indicate good linearity, with all results being around 0.98. The minimum concentration 
each assay is able to detect (assay sensitivity) was determined by analyzing 20 replicates 
of the diluent and calculating the mean±2 standard deviation, which was established as 
the cut-off value (Table 4). Assay sensitivities ranged from 0.000-2.330.  
The normal reference intervals (NRI) are given in Table 5. The NRIs were 
obtained by assaying sera from approximately 100 healthy adult males and calculating 
the mean±2SD. The intervals obtained were significantly increased over those given in 
the manufacturers’ inserts for the PAP assay 
In determining the normal (negative) and abnormal (positive) patient results, cut-
off values from the manufacturers’ inserts were used (Table 6). In this way, diagnostic 
sensitivities of 30.12% (PSA), 20.73% (PAP), and 0.00% (testosterone) were obtained. 
Sensitivities for combined markers are 30.12% (Testosterone and PSA), 43.37% (PAP 
and PSA), and 43.37% (testosterone, PAP, and PSA). Diagnostic sensitivity is the 
proportion of individuals with a disease who test positively with the test in question for 
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that disease. The higher the sensitivity, the more accurate the test is. Similarly, diagnostic 
specificity is the proportion of individuals without the disease who test negatively with 
the test in question. Diagnostic specificities of 91.29% (PSA), 80.38% (PAP), and 
96.80% (testosterone) were obtained, which are all relatively good. Combined 
specificities were 89.15% (testosterone and PSA), 75.11% (PAP and PSA), and 72.77% 
(testosterone, PAP, and PSA). Other diagnostic parameters evaluated are predictive value 
(+), which is the fraction of positive tests that are true positives, predictive value (-), 
which is the fraction of negative tests that are true negatives, and diagnostic efficiency, 
which is the fraction of all test results that are either true positives or true negatives.  
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Table 2 
Assay Precision: Comparison of PSA with PAP and Testosterone using Control Sera 
Within-Run 
Assay N X (ng/mL) SD (ng/mL) %CV 
PSA 2 1.00 0.02 2.00 
PAP 20 2.13 0.89 41.78 
Testosterone 
level 1 
20 4.25 0.99 23.29 
Testosterone 
level 2 
24 19.65 2.11 10.74 
 
Between-Run 
Assay N X (ng/mL) SD (ng/mL) %CV 
PSA 40 1.00 0.02 2.20 
PAP 22 3.51 2.05 58.40 
Testosterone 
level 1 
15 5.11 4.69 91.96 
Testosterone 
level 2 
Not done    
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Table 3 
 
Assay Linearity: Comparison of Linearity of PSA with PAP and Testosterone 
 
Assay R Squared 
PSA 0.9996 
PAP 0.9850 
Testosterone 0.9830 
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Table 4 
 
Assay Sensitivity: Comparison of Sensitivity of PSA with PAP and Testosterone 
 
Assay N X (ng/mL) SD (ng/mL) Range (ng/mL) 
PSA 20 0.00 0.004 0-0.008 
PAP 19 0.32 0.830 0-1.980 
Testosterone 20 1.21 0.560 0-2.330 
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Table 5 
 
Normal Reference Intervals: Comparison of Healthy Adult Reference Intervals for 
Total PSA with PAP and Testosterone 
 
Tumor 
Marker 
N X (ng/mL) SD (ng/mL) Range (ng/mL) 
PSA 80 0.98 0.96 0-2.90 
PAP 101 7.79 14.99 0-37.77 
Testosterone 102 4.44 3.40 0-11.24 
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Table 6 
 
Predictive Values: Comparison of Diagnostic Parameters of PSA, PAP, and 
Testosterone for Prostate Cancer in 551 Patients 
 
Tumor 
Marker 
Sensitivity 
(%) 
Specificity 
(%) 
PV + 
(%) 
PV – 
(%) 
Efficiency 
(%) 
Cut-off 
(%) 
PSA 30.12 91.29 39.06 87.58 81.73 4.00 
PAP 20.73 80.38 15.60 85.29 71.51 5.00 
Testosterone 0.00 96.80 0.00 84.70 82.40 10.00 
Combination 
of 
Testosterone 
and PSA 
30.12 89.15 32.89 87.84 80.29 N/A 
 
Combination 
of PAP and 
PSA 
43.37 75.11 23.53 88.25 70.34 N/A 
 
Combination 
of 
Testosterone, 
PAP, and 
PSA 
43.37 72.77 21.95 87.92 68.35 N/A 
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Graph 1 
PAP Linearity 
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Graph 2 
Testosterone linearity 
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Graph 3 
  
PSA Linearity 
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Discussion 
 Analytical parameters for each of the three testing methods were adequate. As 
previously stated, the normal reference intervals calculated for PAP were considerably 
higher than the manufacturer’s specifications. This was possibly due to a few falsely 
diagnosed subjects or an intrinsic defect with the testing procedure itself. None of the 
diagnostic sensitivities were optimal, but of the three examined, PSA remained the most 
accurate by that measure. The diagnostic specificities obtained were much better, with 
testosterone representing the most specific assay (96.80%). This result was in great 
contrast to the 0% sensitivity of testosterone. The “cutoff points” for testosterone used 
were those of the manufacturer (uncorrected). By adjusting the cutoff points one would 
obtain higher % sensitivity but lower % specificity. PAP specificity (80.38%) was below 
either of the other tests (PSA-91.29%; testosterone-96%). Predictive values (+ and -) 
were similarly comparable. One notable result was the 0% PV+ of testosterone and its 
84.70% PV- value. Consequently, it could be theorized that testosterone has more value 
in ruling out prostate cancer than in confirming it. PAP stayed consistently second or 
third in the comparison of diagnostic parameters. Testosterone had the highest diagnostic 
efficiency (82.40%), followed closely by PSA (81.73%).  
 Concerning the combined marker results, three conclusions may be drawn from 
the data presented. First of all, it is apparent that adding testosterone evaluation to the 
current measurement of PSA does not improve any of the diagnostic capabilities. 
Secondly, measuring both PAP and PSA improves the diagnostic sensitivity alone over 
that of PSA by itself. Finally, combining all three markers in diagnostic evaluation also 
improves only the diagnostic sensitivity over that of PSA alone.  
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Lee, C., et. al stated  “serum prostatic acid phosphatase has been reported as the 
most valuable enzyme marker for the diagnosis of prostate cancer.” (1982). More 
recently however Haese, et. al (2002) wrote, based on further testing, that “most experts 
now agree that PAP analysis has no role in the diagnosis and monitoring of prostate 
cancer and that PSA is clearly the superior marker.” These results confirm those of our 
tests. While PSA does not have the ideal hallmarks of a tumor marker (high sensitivity 
and specificity, PV+ and -, and efficiency), it is comparably the best available within the 
spectrum of this study. Neither of the other markers assayed showed as much consistent 
diagnostic accuracy as PSA. The initial statement by Lee, et. al (1982) that PAP is the 
most valuable marker was most likely made before the major discovery of the assay for 
PSA was widely known. Although PAP is still used in some cases to monitor cancer 
progression and detect tumors that do not produce a sizable increase in PSA 
concentration, it has largely been replaced by PSA due to evidence reported by Haese, et. 
al (2002) and others. These latter reports are in agreement with the findings of this study. 
A strong point of this study is the small number of people directly involved in 
testing the samples. This keeps the amount of human error relatively standard among all 
the testing runs and makes the study more reliable. Also, there was always more than one 
person present during testing to as backup to prevent pipetting error. All the testing kits 
for each tumor marker were from the same company, standardizing the potential 
equipment error. Conversely, the age of some of the samples is a possible weakness due 
to potential sample degradation. Those samples from the Wilford Hall Medical Center 
were several months old, in contrast to the more recent samples from Singing River 
Hospital and Forrest General Hospital. To improve the accuracy of this study, a larger 
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number of samples should be tested from multiple geographic regions. The samples used 
should be as fresh as possible, and only thawed once, when tested.     
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Conclusion 
From the data, it was concluded that the test for prostate specific antigen is the 
most accurate and efficient screen for prostate cancer. The hypothesis that prostatic acid 
phosphatase would be a better screening test was rejected. PAP is not more efficient than, 
or even as efficient as PSA in the diagnosis of prostate cancer. The sensitivity and 
specificity were both lower than that of PSA, although the results were relatively close. 
This finding is in line with other studies of the same nature.   
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